SCP 26
July 3 to July 6, 2017 WIPO’s Page for the Meeting SCP26 – Agreement reached on future work reached at WIPO Standing Committee on the Law of Patents (6 July 2017) WIPO SCP 26 KEI Side Event: Running royalties as… Continue Reading
Access to Medicine
Negotiations on R&D funding agreements
1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading
Competition
USDOJ 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY STANDARD SETTING AND COMPETITION November 8, 2012 COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012 CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER… Continue Reading
Legislation on transparency of R&D costs in biopharmaceutical sector
This page features KEI blog posts, testimony, comments, and research on the transparency of the costs of research and development in the pharmaceutical sector. United States Transparency Legislation 16 March 2017: KEI testifies before a Maryland House of Delegates Subcommittee… Continue Reading
KEI Reaction to the White House CEA Paper on Biopharmaceutical Pricing Home and Abroad
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
KEI Comments to USTR regarding 2018 Special 301 list
Coalition calls upon Congress to pass CREATES Act
Knowledge Ecology International and 43 other health-care interested groups are calling on Congress to pass the CREATES Act. The CREATES Act, or the “Creating and Restoring Equal Access To Equivalent Samples Act of 2017”, is a bipartisan proposal to speed… Continue Reading
WIPO’s Standing Committee on the Law of Patents (SCP)
Special 301
The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
2010 Fabrazyme March-In Request
More on Fabry here: https://keionline.org/fabry NIH rejects Fabrazyme March-In Petition December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying… Continue Reading